Q-omics provides the consensus-scored MCHR2 profile across patient tissues and cancer cell-line models. MCHR2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MCHR2 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, MCHR2 RNA expression shows 11,235 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where MCHR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCHR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCHR2 survival associations across molecular data types. MCHR2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCHR2 RNA expression–survival associations across cancer types. High MCHR2 expression shows unfavorable associations in ACC, SARC, READ, KIRC and KIRP, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MCHR2 RNA expression.
This table summarizes MCHR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MCHR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCHR2 shows lower tumor expression in COAD and READ and higher tumor expression in HNSC, LUSC and LUAD. The COAD box plot shows higher MCHR2 RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p < 0.001).
This table shows molecular features associated with MCHR2 in patient tissues and cancer cell lines. In patient samples, MCHR2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MCHR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
